STAT+: Launch prices for new medicines dipped slightly last year but remain high, analysis finds
The median net price for 202 newly launched medicines rose by 35%, to $257,000 last year from $173,000 in 2022.
Read at source →Source
STAT News
Medicine, biotech, and health policy
Health · 721 articles · page 2 of 21 · fetched about 1 hour ago
STAT+: The key health care ballot measures we’re watching in the midterms
State fights over issues like transgender rights and Medicaid offer clues to where Americans stand on contentious…
Read at source →
Opinion: Resident physicians may lose some of their most important work hour protections
“It is important to create barriers between high intensity shifts with physical, intellectual, and emotional burden to…
Read at source →
AdSponsoredSiguimi
Pure chronological social — no algorithm
See who you follow, newest first. Free to join. Posts that stay visible — not buried by an algo.
Join siguimi.com →
Trump orders creation of NIH division, task force on women’s health
Melania Trump said a new research and policy initiative will set “a new standard for women’s health.”
Read at source →
Opinion: I was a Theranos whistleblower. In ‘You Can See Everything,’ Elizabeth Holmes is still lying
A more accurate name would be “You Can See Everything That We Chose To Point The Camera At,”Theranos whistleblower…
Read at source →
STAT+: The umpires getting rich off surprise medical bills, and MLB job lock
We dig into trust, prices, and a bit of baseball in this week's Health Care Inc. newsletter.
Read at source →
STAT+: China moves to restrict foreign biotech acquisitions
China is proposing new restrictions on foreign acquisitions of critical biopharma technologies, as the country seeks to…
Read at source →
Two former Republican lawmakers say the GOP’s vaccine position is a liability
The Republican party’s confusing messaging on vaccines is going to hurt candidates in the midterms, two former GOP…
Read at source →
STAT+: Pharmalittle: We’re reading about Roche investments in Germany, a Gilead bowel disease drug, and more
Roche is reviewing all future investments in Germany over health care cost-cutting policies, with a top executive…
Read at source →
STAT+: Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds
An oral treatment from Gilead Sciences eliminated the symptoms experienced by patients with a type of inflammatory…
Read at source →
STAT+: Top immunology association divided over $8.4-billion California ballot measure to fund the field, emails show
Internal emails obtained by STAT show that the American Association of Immunologists is sharply divided over…
Read at source →
STAT+: Does Isomorphic Labs have what it takes to revolutionize drugmaking?
Isomorphic Labs wants to turn its technology into an engine for new medicines. The question now is whether — and how —…
Read at source →
Opinion: My mother killed herself. I wish assisted suicide had been an option
“Sometimes mental illness is terminal,” Torie Bosch writes in a personal essay about medical aid in dying for…
Read at source →
Opinion: Measles is back — and becoming a midterm liability for Republicans
“Silence on vaccines is becoming a dealbreaker for voters who would otherwise vote Republican,” write physicians and…
Read at source →
STAT+: How the No Surprises Act’s nonprofit arbitrators are operating like ‘mini gods’ and getting rich doing it
A STAT investigation found that several nonprofits are raking in massive sums by acting as arbitrators in a program…
Read at source →
STAT+: Cambridge scientist David Sabatini speaks out after courtroom victory: ‘The hardest years of my life’
"The hardest years of my life," is how Cambridge scientist David Sabatini describes the time since his downfall from…
Read at source →STAT+: Jury rules in favor of ousted Cambridge scientist David Sabatini, with $6 million in damages to be awarded
A jury awarded $6 million in damages to scientist David Sabatini, whose career imploded after he was accused by a much…
Read at source →
Hospitals’ next lucrative bet — longevity clinics
On this week's “The Readout LOUD,” STAT's biotech podcast, we discuss the booming industry of longevity health.
Read at source →STAT+: Pharmalittle: We’re reading about an HHS peptide push, Trump’s pharma stock holdings, and more
The Trump administration is proceeding with a plan to allow compounding pharmacies to produce certain peptides
Read at source →
STAT+: RevMed’s pancreatic cancer drug nears European approval
Following a green light from the FDA, European regulators have now recommended the approval of Revolution Medicines'…
Read at source →
What to read before you go see that new documentary on Elizabeth Holmes
Ahead of "You Can See Everything" hitting theaters, let's rewind the last decade and review some of the most…
Read at source →
STAT+: Coerced sex or a jealous ex? Jury weighs dueling accounts of star scientist David Sabatini’s downfall
Was molecular biologist David Sabatini a manipulative mentor who coerced a younger colleague into sex? Or was he the…
Read at source →
STAT+: In DOGE’s aftermath, federal health workers bristle at new performance reviews
Changes to the annual performance review process are the latest flashpoint in tensions between federal workers across…
Read at source →
Opinion: Is Milton Friedman to blame for America’s health care woes?
Health policy experts John McDonough and Stuart Butler debate where the U.S. medical system went wrong — and how to fix…
Read at source →
Opinion: I thought I knew why patients stopped taking their medicine. I was wrong
Patients can understand that medication is necessary and still struggle with what taking it means.
Read at source →
Trump administration advances plan for peptide drugs favored by RFK Jr.
U.S. health officials are moving ahead with a plan to allow specialty pharmacies to produce certain peptides, a class…
Read at source →
Merck and Moderna have ‘lot of exploring to do’ after initial cancer vaccine success
Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA…
Read at source →
The Trump administration is doubling down on health care fraud investigations
At the STAT Summit, the Department of Justice offered up a warning for health care executives: Don’t be another…
Read at source →
Mass. lawmaker Auchincloss favors boosting U.S. biotech over targeting China
Rep. Jake Auchincloss (D-Mass.) has some advice for fellow lawmakers: unapologetically support the biotech industry.
Read at source →
STAT+: Former FDA commissioners Califf, Gottlieb, Sharpless lay into current HHS leadership
Former FDA commissioners Rob Califf (Obama and Biden administrations), Scott Gottlieb, and Ned Sharpless (both from the…
Read at source →
STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer
Verastem Oncology reports encouraging early results for its KRAS G12D inhibitor, which it’s studying in more than 200…
Read at source →
After a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forward
A schoolteacher diagnosed with melanoma provides an inside look at what it was like to be treated with a cancer vaccine…
Read at source →STAT+: Pharmalittle: We’re reading about former FDA head calling DOGE a ‘disaster,’ an AstraZeneca AI deal, and more
Three former FDA chiefs lit into the Trump administration, criticizing the now former FDA officials who oversaw a…
Read at source →
STAT+: ‘AI sandboxes’ are all the rage. Advocates scramble to control their future
In this edition of STAT's Health Tech newsletter: The groups vying to shape regulations that'd govern state AI…
Read at source →
Kenya reports second Ebola case
Kenya reports a second Ebola case. Meanwhile, the situation in Congo is still quite dire. Authorities have confirmed…
Read at source →
STAT+: On Wall Street, there’s trouble stirring for biotech
On Wall Street, the real trouble for biotech, and the reason for investor angst, lies below the surface.
Read at source →